Acute Myelogenous Leukemia with the t(7;7)(p15;p22) Translocation, a Novel Simple Variant of t(7;11)(p15;p15) Translocation: First Description

Case Reports in Hematology ◽

10.1155/2021/5529669 ◽

2021 ◽

Vol 2021 ◽

pp. 1-4

Author(s):

Motoharu Shibusawa

Keyword(s):

Acute Myelogenous Leukemia ◽

Degradation Products ◽

Homeobox Genes ◽

Multiple Organ ◽

Myelogenous Leukemia ◽

Genetic Abnormality ◽

Novel Variant ◽

Acute Myelogenous ◽

Simple Variant ◽

French American British

The t(7;11)(p15;p15) translocation is a recurrent genetic abnormality associated with acute myelogenous leukemia (AML). The translocation results in a fusion between the nucleoporin 98 and homeobox genes. We describe a case of AML with t(7; 7)(p15;p22) translocation, which is a novel simple variant of the t(7;11)(p15;p15) translocation. A 66-year-old woman presented with subcutaneous hemorrhage in both forearms. Laboratory test revealed hyperleukocytosis (white blood cell count: 97,800 cells/µL (blasts, 51.0%)), anemia (hemoglobin level: 7.6 g/dL), thrombocytopenia (platelet count: 6.5 × 104/μL), and hyperfibrinolysis (elevated d-dimer level: 12.4 µg/mL; fibrin/fibrinogen degradation products: 26.9 µg/mL). The patient was diagnosed with AML; the blast morphology was unclassifiable according to the French-American-British classification. Flow cytometry CD45 gating revealed that the blasts expressed CD34, CD13, CD33, and CD117. G-banding of tumor cells revealed the t(7;7)(p15;p22) translocation [20/20]. The patient underwent chemotherapy. At 48 days of admission, the patient died of multiple organ failure. The t(7;7)(p15;p22) translocation involved chromosome 7p15, indicating its association with the homeobox genes. To the best of our knowledge, this is the first report of a patient with AML with the t(7;7)(p15;p22) translocation, which is a simple novel variant of the t(7;11)(p15;p15) translocation.

Download Full-text

t(8;21;14)(q22;q22;q24) is a novel variant of t(8;21) with chimeric transcripts of AML1-ETO in acute myelogenous leukemia

Cancer Genetics and Cytogenetics ◽

10.1016/s0165-4608(01)00550-7 ◽

2002 ◽

Vol 132 (2) ◽

pp. 133-135 ◽

Cited By ~ 12

Author(s):

Fumihiro Ishida ◽

Mayumi Ueno ◽

Hitoshi Tanaka ◽

Hideki Makishima ◽

Kenichi Suzawa ◽

...

Keyword(s):

Acute Myelogenous Leukemia ◽

Myelogenous Leukemia ◽

Chimeric Transcripts ◽

Novel Variant ◽

Acute Myelogenous

Download Full-text

Secondary acute myelogenous leukemia following safe exposure to etoposide.

Journal of Clinical Oncology ◽

10.1200/jco.1997.15.4.1583 ◽

1997 ◽

Vol 15 (4) ◽

pp. 1583-1586 ◽

Cited By ~ 52

Author(s):

K C Stine ◽

R L Saylors ◽

J R Sawyer ◽

D L Becton

Keyword(s):

Acute Myelogenous Leukemia ◽

Hodgkin's Disease ◽

Hodgkin’S Disease ◽

Disease Patient ◽

Myelogenous Leukemia ◽

Chromosome 11 ◽

Acute Myelogenous ◽

Involved Field ◽

Involved Field Radiotherapy ◽

French American British

PURPOSE To present two patients as illustrations of the risk of developing secondary acute myelogenous leukemia (sAML) when theoretically safe doses of etoposide (VP-16) are used. PATIENTS AND METHODS Patient no. 1 was a 15-year-old white girl diagnosed with stage IIa Hodgkin's disease. She was treated with a combination of vincristine, doxorubicin, bleomycin, and VP-16 (2 g/m2 total) over 4 months, followed by 25.5 Gy of involved-field radiotherapy. Patient no. 2 was an 11-year-old white boy diagnosed with virus-associated hemophagocytic syndrome (VAHS). He was treated with VP-16 intravenously (IV) and orally (0.3 g and 2.8 g/m2, respectively). RESULTS Patient no. 1 developed AML 16 months from the diagnosis of Hodgkin's disease. Patient no. 2 developed AML 26 months from diagnosis. Both bone marrows were consistent with French-American-British (FAB) M4 disease. Both patients had abnormalities of the long arm of chromosome 11. CONCLUSION The use of low-dose or oral VP-16 can be associated with the development of sAML. Clinicians should be cautious in the use of VP-16 in low-risk diseases.

Download Full-text

Evaluation of Bone Marrow Specimens With Acute Myelogenous Leukemia for CD34, CD15, CD117, and Myeloperoxidase

Archives of Pathology & Laboratory Medicine ◽

10.5858/2001-125-1063-eobmsw ◽

2001 ◽

Vol 125 (8) ◽

pp. 1063-1069 ◽

Cited By ~ 2

Author(s):

Cherie H. Dunphy ◽

Jacek M. Polski ◽

H. Lance Evans ◽

Laura J. Gardner

Keyword(s):

Bone Marrow ◽

Acute Myelogenous Leukemia ◽

Myelogenous Leukemia ◽

Flow Cytometric ◽

Acute Myelogenous ◽

Cd34 Expression ◽

French American British ◽

Higher Sensitivity

Abstract Context.—Immunophenotyping of bone marrow (BM) specimens with acute myelogenous leukemia (AML) may be performed by flow cytometric (FC) or immunohistochemical (IH) techniques. Some markers (CD34, CD15, and CD117) are available for both techniques. Myeloperoxidase (MPO) analysis may be performed by enzyme cytochemical (EC) or IH techniques. Objective.—To determine the reliability of these markers and MPO by these techniques, we designed a study to compare the results of analyses of these markers and MPO by FC (CD34, CD15, and CD117), EC (MPO), and IH (CD34, CD15, CD117, and MPO) techniques. Materials and Methods.—Twenty-nine AMLs formed the basis of the study. These AMLs all had been immunophenotyped previously by FC analysis; 27 also had had EC analysis performed. Of the AMLs, 29 had BM core biopsies and 26 had BM clots that could be evaluated. The paraffin blocks of the 29 BM core biopsies and 26 BM clots were stained for CD34, CD117, MPO, and CD15. These results were compared with results by FC analysis (CD34, CD15, and CD117) and EC analysis (MPO). Results.—Immunodetection of CD34 expression in AML had a similar sensitivity by FC and IH techniques. Immunodetection of CD15 and CD117 had a higher sensitivity by FC analysis than by IH analysis. Detection of MPO by IH analysis was more sensitive than by EC analysis. There was no correlation of French-American-British (FAB) subtype of AML with CD34 or CD117 expression. Expression of CD15 was associated with AMLs with a monocytic component. Myeloperoxidase reactivity by IH analysis was observed in AMLs originally FAB subtyped as M0. Conclusions.—CD34 can be equally detected by FC and IH techniques. CD15 and CD117 are better detected by FC analysis and MPO is better detected by IH analysis.

Download Full-text